Actionable news
All posts from Actionable news
Actionable news in OMER: Omeros Corporation,

Omeros Announces Pricing of Public Offering of Common Stock

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system, announced today the pricing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $22.75 per share, before deducting underwriting discounts and other estimated offering expenses. This bought deal offering is expected to close on or about August 18, 2017, subject to the satisfaction of customary closing conditions. In addition, Omeros has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock.

Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering. H.C. Wainwright & Co. is acting as lead manager and JonesTrading Institutional Services LLC and Maxim Group LLC are acting as co-managers in the offering.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to funding research and development for its OMS721 programs and clinical trials, pre-clinical studies, manufacturing and other costs associated with advancing its product candidates toward Biologic License Application and New Drug Application submissions. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products...